Pure Global AI
NCT06123897Not yet recruiting

Establishing a Clinical Database and Biobank for Schizophrenia：A Cohort Study

Central South UniversityClinicalTrials.govother
Verified
Study focus
Disease/Condition
Schizophrenia
Drug/Device/Intervention
Regular follow-up assessments without intervention.
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Central South University
Location
Changsha, China
Timeline & enrollment
Phase
N/A
Start date
Dec 01, 2023
End date
Dec 31, 2028
Enrollment
2000 participants
Primary outcome

Change of clinical symptoms by Positive And Negative Syndrome Scale,Change of clinical symptoms by Clinical Global Impression,Change of the MATRICS Consensus Cognitive Battery score

Summary

This project intends to employ standardized diagnostic criteria and clinical assessment
 procedures to establish a comprehensive cohort of patients with schizophrenia, encompassing
 all age groups and disease stages, with follow-up periods exceeding one year. The goal is to
 create an internationally high-standard clinical cohort database and biobank for
 schizophrenia. Through a multidimensional assessment framework, the project aims to further
 investigate the etiology of schizophrenia, patterns of disease progression, and clinical
 outcomes. By periodically capturing dynamic information on risk and preventive factors, the
 project aims to achieve early diagnosis, early treatment, and improved prognosis for
 patients. Additionally, it seeks to explore potential biomarkers within the realm of
 precision medicine that can predict treatment efficacy, providing viable tools for precision
 healthcare and clinical decision-making in the field of schizophrenia.

ICD-10 classifications
SchizophreniaSimple schizophreniaSchizophrenia, unspecifiedOther schizophreniaParanoid schizophrenia
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06123897
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06123897 through Pure Global AI's free database. This phase not specified trial is sponsored by Central South University and is currently Not yet recruiting. The study focuses on Schizophrenia. Target enrollment is 2000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.